Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.81 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.81 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | IL1B | P01584 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19692456 | 0.95 | CRBN (0.80) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21062689 | 0.94 | CRBN (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20975160 | 0.94 | CRBN (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL24621026 | 0.94 | CRBN (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22500886 | 0.94 | CRBN (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19692300 | 0.94 | CRBN (0.78) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL30275753 | 0.94 | CRBN (0.78) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21294522 | 0.93 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19692342 | 0.93 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23832857 | 0.93 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618755-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023116934-A1 | KRASG12D PROTEIN HYDROLYSIS REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州泽璟生物制药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-115043817-A | SOS1 proteolysis regulator and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022148459-A1 | CLASS OF NOVEL SMAD3 PROTEIN DEGRADERS AND APPLICATION THEREOF | 和径医药科技（上海）有限公司 | 2022-07-14 | — | — | WO | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3746135-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | Foghorn Therapeutics Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | DDB1 486/4885CRBN 287/4885IKZF3 590/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | DDB1 486/4885CRBN 287/4885IKZF3 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.